Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03818685
Title Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease (BreastImmune03)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Centre Leon Berard
Indications

triple-receptor negative breast cancer

Therapies

Ipilimumab + Nivolumab

Capecitabine

Age Groups: adult | senior
Covered Countries


No variant requirements are available.